Epidermal growth factor receptor: is a novel therapeutic target for pancreatic cancer?
Expression of epidermal growth factor receptors (EGFR) is exaggerated in pancreatic adenocarcinoma and activation of EGFR appears to have an important role in the growth and differentiation of this and in other tumors. Therefore, blockade or inactivation of EGFR by monoclonal antibodies or by tyrosine kinase inhibitors has significant potential as an effective anti-cancer therapy. One of the very recent significant developments in the field of molecular biology involves the use of antisense of EGFR or EGFR gene silencing in pancreatic cancer cells as a potential targeted therapy for patients with pancreatic adenocarcinoma.
Dhar
Animesh
A
Cancer Research Unit, Department of Veterans Affairs Medical Center, 4801 East Linwood Boulevard, Kansas City, MO 64128-2226, USA. Animesh.Dhar@med.va.gov <Animesh.Dhar@med.va.gov>
Mehta
Smita
S
Banerjee
Snigdha
S
Dhar
Kakali
K
Dhar
Gopal
G
Sengupta
Krishanu
K
Ray
Gibanananda
G
Banerjee
Sushanta K
SK
Campbell
Donald R
DR
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D004354:Drug Screening Assays, Antitumor; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D066246:ErbB Receptors